empagliflozin
boehringer ingelheim
['empag', 'empakidney']
dr david preiss presents cv outcomes from #empakidney. #sglt2i . in ckd patients, #empaglifozin conferred similar reduction in primary outcome among patients with or without baseline cv disease. fewer cv deaths than expected. #aha22 
Johns Hopkins Medicine. Associate Professor, Cardiology. Co-Editor in Chief @AJPCardio. #WomenHeartHealth #CardioObstetrics #cvPrev #echofirst She/her #BeKind